AGPAT2 Human shRNA Plasmid Kit (Locus ID 10555)
CAT#: TL314894
AGPAT2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (4)
Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
CNY 4,070.00
Specifications
Product Data | |
Product Name | AGPAT2 Human shRNA Plasmid Kit (Locus ID 10555) |
Locus ID | 10555 |
UniProt ID | O15120 |
Synonyms | 1-AGPAT2; BSCL; BSCL1; LPAAB; LPAAT-beta |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | AGPAT2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 10555). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001012727, NM_006412, NM_006412.1, NM_006412.2, NM_006412.3, NM_001012727.1, BC000026, BC004529, BC004529.2, BC007269, BC019292, NM_001012727.2, NM_006412.4 |
Summary | This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Terapia génica y celular para la corrección de la Lipodistrofia Congénita Generalizada
,Moro Muñoz, RM;,
Thesis
[AGPAT2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...